


Patent Claims

1. Compounds of the formula I



in which

- X denotes CH or N,
- Y denotes Het²-diyl,
- R¹ denotes O(CH₂)_nHet¹, NH(CH₂)_nHet¹, OA, NHA, NA₂, O(CH₂)_nCyc or NH(CH₂)_nCyc,
- R² denotes H, A, Ar¹, (CH₂)_nHet³, CN, (CH₂)_nCyc, CONH₂, COOA, (CH₂)_nOH, (CH₂)_nOA, (CH₂)_nNH₂, (CH₂)_nNHA or (CH₂)_nNA₂,
- Ar¹ denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, COOH, COOA, CN, CONH₂, NHSO₂A, NO₂, NH₂, NHA, NA₂, SO₂NH₂, SO₂NHA, SO₂NA₂, CHO and/or SO₂A,
- Het¹ denotes dihydropyrrolyl, pyrrolidinyl, azetidiny, tetrahydroimidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, morpholinyl, hexahydropyridazinyl, hexahydropyrimidinyl, 1,3-dioxolanyl, tetrahydropyranyl or piperazinyl, each of which is unsubstituted or monosubstituted by OF-, COOA, CONH₂, COA and/or A,
- Het² denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, indolyl, iso-indolyl, benzimidazolyl, indazolyl, quinolyl, 1,3-benzodioxolyl, benzothio-phenyl, benzofuranyl, imidazopyridyl, 5,6,7,8-tetrahydropyrido[4,3-d]-pyrimidin-2-yl or furo[3,2-b]pyridyl, each of which is unsubstituted or monosubstituted by Hal, A, OH, =O, OA, CN, COOA, COOH, CONH₂ and/or NHCOA,

Het³ denotes dihydropyrrolyl, pyrrolidinyl, azetidiny, tetrahydroimidazolyl, tetrahydrofuranyl, dihydropyrazolyl, tetrahydropyrazolyl, dihydropyridyl, tetrahydropyridyl, dihydropyranyl, tetrahydropyranyl, piperidinyl, morpholinyl, hexahydropyridazinyl, hexahydropyrimidinyl, 1,3-dioxolanyl, piperazinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, quinolyl, 1,3-benzodioxolyl, benzothiophenyl, benzofuranyl, imidazopyridyl or fluoro[3,2-b]pyridyl, each of which is unsubstituted or mono- or disubstituted by Hal, A, OH, OA, CN, COOA, COOH, CONH₂, CONHA, CONA₂, COA, COCH₂NH₂, COCH₂NHA, COCH₂NA₂, (CH₂)_nCyc and/or NHCOA,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two non-adjacent CH and/or CH₂ groups may be replaced by N, O and/or S atoms and/or, in addition, 1-7 H atoms may be replaced by F and/or Cl,

Cyc denotes cyclic alkyl having 3, 4, 5, 6 or 7 C atoms which is unsubstituted or monosubstituted by CN, (CH₂)_nOH or A,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2, 3 or 4,

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. Compounds according to Claim 1 in which

R¹ denotes O(CH₂)_nHet¹ or O(CH₂)_nCyc,

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

3. Compounds according to Claim 1 or 2 in which

Ar¹ denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to one or more of Claims 1-3 in which
Het¹ denotes pyrrolidinyl, piperidinyl, morpholinyl or tetrahydropyranyl, each of which is unsubstituted or monosubstituted by COA,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
5. Compounds according to one or more of Claims 1-4 in which
Het² denotes thienyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyridazinyl, thiazolyl, pyrimidyl, indolyl, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl or benzofuranyl, each of which is unsubstituted or monosubstituted by =O or OA,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
6. Compounds according to one or more of Claims 1-5 in which
Het³ denotes pyrrolidinyl, azetidinyl, tetrahydrofuranyl, dihydropyranyl, tetrahydropyranyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, piperazinyl, morpholinyl, furyl, thienyl, pyrazolyl, benzofuranyl or pyridyl, each of which is unsubstituted or monosubstituted by A,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
7. Compounds according to one or more of Claims 1-6 in which
A denotes unbranched or branched alkyl having 1-8 C atoms, in which one or two non-adjacent CH and/or CH₂ groups may be replaced by N and/or O atoms and/or, in addition, 1-7 H atoms may be replaced by F,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
8. Compounds according to one or more of Claims 1-7 in which
X denotes CH or N,

- Y denotes Het²-diyl,
- R¹ denotes O(CH₂)_nHet¹ or O(CH₂)_nCyc,
- R² denotes H, A, Ar¹, (CH₂)_nHet³, CN, (CH₂)_nCyc, CONH₂, COOA, (CH₂)_nOH, (CH₂)_nOA, (CH₂)_nNH₂, (CH₂)_nNHA or (CH₂)_nNA₂,
- Ar¹ denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
- Het¹ denotes pyrrolidinyl, piperidinyl, morpholinyl or tetrahydropyranyl, each of which is unsubstituted or monosubstituted by COA,
- Het² denotes thienyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyridazinyl, thiazolyl, pyrimidyl, indolyl, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl or benzofuranyl, each of which is unsubstituted or monosubstituted by =O or OA,
- Het³ denotes pyrrolidinyl, azetidinyl, tetrahydrofuranyl, dihydropyranyl, tetrahydropyranyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, piperazinyl, morpholinyl, furyl, thienyl, pyrazolyl, benzofuranyl or pyridyl, each of which is unsubstituted or monosubstituted by A,
- A denotes unbranched or branched alkyl having 1-8 C atoms, in which one or two non-adjacent CH and/or CH₂ groups may be replaced by N and/or O atoms and/or, in addition, 1-7 H atoms may be replaced by F,
- Cyc denotes cyclic alkyl having 3, 4, 5, 6 or 7 C atoms which is unsubstituted or monosubstituted by CN, (CH₂)_nOH or A,
- n denotes 0, 1, 2, 3 or 4,
- and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.




9. Compounds according to Claim 1, selected from the group





Compound No.	Name and/or structure
"A1"	2-(Tetrahydropyran-4-yloxy)-5-{2-[1-(3-trifluoromethylphenyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}benzonitrile

"A2"	5-[2-[1-(1-Methylpiperidin-4-yl)-1H-pyrazol-4-ylamino]pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A3"	5-[2-([3,3']Bipyridinyl-6-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A4"	5-[2-(5-Methylisoxazol-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A5"	5-[2-(1-Methyl-1H-pyrazol-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A6"	5-[2-(2-Furan-2-ylmethyl-2H-pyrazol-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A7"	5-[2-(5-Morpholin-4-ylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A8"	5-[2-(1-Phenyl-1H-pyrazol-4-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A9"	5-[2-[5-(1H-Pyrazol-4-yl)pyridin-2-ylamino]pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A10"	5-[2-(5-tert-Butyl-1H-pyrazol-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A11"	6-[4-[3-Cyano-4-(tetrahydropyran-4-yloxy)phenyl]pyridin-2-ylamino]nicotinonitrile
"A12"	5-[2-(5-Cyclopropyl-2H-pyrazol-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A13"	2-(Tetrahydropyran-4-yloxy)-5-[2-(5-trifluoromethylpyridin-2-ylamino)pyridin-4-yl]benzonitrile
"A14"	5-[2-(Pyrimidin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A15"	5-[2-(5-Hydroxymethylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A16"	5-[2-(1-Piperidin-4-yl-1H-pyrazol-4-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile

"A17"	2-{4-[3-Cyano-4-(tetrahydropyran-4-yloxy)phenyl]pyridin-2-yl-amino}isonicotinonitrile
"A18"	5-[2-(4-Hydroxymethylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A19"	5-{4-[3-Cyano-4-(tetrahydropyran-4-yloxy)phenyl]pyridin-2-yl-amino}benzofuran-2-carboxamide
"A20"	5-[2-[1-(2,2-Difluoroethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A21"	5-[2-[1-(2-Piperidin-4-ylethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A22"	5-[2-[1-(2-Morpholin-4-ylethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A23"	5-[2-[1-(3-Methoxypropyl)-1H-pyrazol-4-ylamino]pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A24"	5-[2-[1-(2-Cyanocyclopropylmethyl)-1H-pyrazol-4-ylamino]-pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A25"	5-[2-(1-Azetidin-3-yl-1H-pyrazol-4-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A26"	5-[2-[1-[(1S,2S)-2-Hydroxymethylcyclopropylmethyl]-1H-pyrazol-4-ylamino]pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)-benzonitrile
"A27"	5-[2-[1-(Tetrahydrofuran-3-ylmethyl)-1H-pyrazol-4-ylamino]-pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A28"	5-[2-(1-Pyrrolidin-3-yl-1H-pyrazol-4-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A29"	5-[2-(1-{2-[1-(2-Hydroxyacetyl)piperidin-4-yl]ethyl}-1H-pyrazol-4-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A30"	5-[2-(1-{2-[1-(2-Aminoacetyl)piperidin-4-yl]ethyl}-1H-pyrazol-4-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A31"	5-[2-(3-tert-Butylisoxazol-5-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile

"A32"	2-(Tetrahydropyran-4-yloxy)-5-{2-[1-(3-trifluoromethylphenyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}benzonitrile
"A33"	5-[2-(1-Methyl-1H-pyrazol-3-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A34"	5-[2-(1H-Pyrazol-4-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A35"	5-{2-[1-(2-Methoxyethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A36"	2-(Tetrahydropyran-4-yloxy)-5-[2-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-ylamino)pyridin-4-yl]benzonitrile
"A37"	6-{4-[3-Cyano-4-(tetrahydropyran-4-yloxy)phenyl]pyridin-2-ylamino}nicotinamide
"A38"	5-{2-[1-(2-Pyrazol-1-ylethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A39"	5-{2-[1-(2-Morpholin-4-ylethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A40"	5-[2-(1-Pyrrolidin-3-yl-1H-pyrazol-4-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A41"	5-{2-[1-(Tetrahydrofuran-3-ylmethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A42"	5-{4-[3-Cyano-4-(tetrahydropyran-4-yloxy)phenyl]pyrimidin-2-ylamino}benzofuran-2-carboxamide
"A43"	5-{2-[1-(2-Pyrazol-1-ylethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A44"	5-{2-[1-(2,2-Difluoroethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A45"	5-{2-[1-(2-Piperidin-4-ylethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A46"	5-{2-[1-(3-Methoxypropyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile

"A47"	5-{2-[5-(3,6-Dihydro-2H-pyran-4-yl)pyridin-2-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A48"	5-[2-(1',2',3',6'-Tetrahydro-[3,4']bipyridinyl-6-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A53"	
"A58"	
"A59"	

"A60"	 <chem>CN1CCCC1COc2ccc(C#N)cc2Nc3ccncc3n4cccnc4</chem>
"A61"	 <chem>OCCN1CCCC1COc2ccc(C#N)cc2Nc3ccncc3n4cccnc4</chem>
"A62"	 <chem>CN1CCCC1N2CCCC2COc3ccc(C#N)cc3Nc4ccncc4n5cccnc5</chem>
"A63"	 <chem>CN1CCCC1COc2ccc(C#N)cc2Nc3ccncc3n4cccnc4N5CCNCC5</chem>

"A64"	5-[2-(1-Piperidin-4-yl-1H-pyrazol-4-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A65"	2-{4-[3-Cyano-4-(tetrahydropyran-4-yloxy)phenyl]pyridin-2-ylamino}isonicotinic acid
"A66"	5-[2-(5-Piperidin-4-ylpyrimidin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A67"	5-{2-[1-((1S,2S)-2-Hydroxymethylcyclopropylmethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A68"	5-[2-(1-Methyl-6-oxo-1,6-dihydropyridazin-3-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A69"	5-[2-(6-Oxo-1,6-dihydropyridazin-3-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A70"	5-[2-(4-Hydroxymethylpyridin-2-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A71"	5-[2-(6-Piperidin-4-ylpyridazin-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A72"	5-[2-(5-Piperidin-4-ylpyrazin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A73"	5-{2-[1-(4-Hydroxycyclohexyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A74"	5-[2-(1',2',3',4',5',6'-Hexahydro-[4,4']bipyridinyl-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A75"	5-[2-[1-(2-Hydroxyethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A76"	5-[2-(2-Methoxy-1',2',3',6'-tetrahydro-[3,4']bipyridinyl-6-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A77"	5-[2-(4-Aminomethylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A78"	5-[2-(1'-Methyl-1',2',3',4',5',6'-hexahydro-[4,4']bipyridinyl-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile

"A79"	5-{2-[1-(2-Hydroxyethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A80"	5-[2-(5-Methylisoxazol-3-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A81"	5-[2-(4-Dimethylaminomethylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A82"	5-[2-(4-Morpholin-4-ylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A83"	5-{2-[1-(2-Pyrrolidin-1-ylethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A84"	5-{2-[4-(4-Methylpiperazin-1-yl)pyridin-2-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A85"	5-[2-(6-Morpholin-4-ylpyrazin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A86"	5-{2-[4-(5,6-Dihydro-4H-pyran-2-yl)pyridin-2-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A87"	5-[2-(4-Cyclopropylthiazol-2-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A88"	5-{2-[5-(2-Oxa-6-azaspiro[3.3]hept-6-ylmethyl)pyridin-2-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A89"	5-[2-(4-Piperidin-4-ylpyrimidin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A90"	5-[2-(6-Morpholin-4-ylpyridazin-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A91"	5-[2-(1',2',3',4',5',6'-Hexahydro-[2,4']bipyridinyl-6-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A92"	5-[2-[6-(5,6-Dihydro-4H-pyran-2-yl)pyrazin-2-ylamino]pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A93"	5-[2-(4-Methyloxazol-2-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile


"A94"	2-Cyclobutylmethoxy-5-{2-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl-amino]pyrimidin-4-yl}benzonitrile
"A95"	2-Cyclobutylmethoxy-5-{2-[1-((1S,2S)-2-hydroxymethyl)cyclopropylmethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}benzonitrile
"A96"	5-[2-(6-Piperidin-4-ylpyrazin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A97"	2-Cyclobutylmethoxy-5-{2-[1-(4-hydroxycyclohexyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}benzonitrile
"A98"	2-(Tetrahydropyran-4-yloxy)-5-{2-[5-(tetrahydropyran-4-yl)-pyrazin-2-ylamino]pyridin-4-yl}benzonitrile
"A99"	5-[2-(5-Hydroxymethylpyrazin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A100"	2-(Tetrahydropyran-4-yloxy)-5-{2-[6-(tetrahydropyran-4-yl)-pyridazin-3-ylamino]pyridin-4-yl}benzonitrile
"A101"	5-{2-[1-(4-Hydroxycyclohexyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A102"	5-[2-(3-Hydroxymethylpyrazin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A103"	2-Cyclobutylmethoxy-5-{2-[1-(2-methoxyethyl)-1H-pyrazol-4-yl-amino]pyrimidin-4-yl}benzonitrile
"A104"	2-Cyclopropylmethoxy-5-[2-(1H-pyrazol-4-ylamino)pyridin-4-yl]-benzonitrile
"A105"	2-Cyclopropylmethoxy-5-{2-[1-(2-methoxyethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}benzonitrile
"A106"	2-Cyclopropylmethoxy-5-[2-(5-hydroxymethylpyridin-2-ylamino)-pyridin-4-yl]benzonitrile
"A107"	2-Cyclopropylmethoxy-5-[2-(1-piperidin-4-yl-1H-pyrazol-3-yl-amino)pyridin-4-yl]benzonitrile
"A108"	2-Cyclopropylmethoxy-5-[2-(5-morpholin-4-ylpyridin-2-ylamino)-pyridin-4-yl]benzonitrile

"A109"	2-Cyclobutylmethoxy-5-[2-(1H-pyrazol-4-ylamino)pyridin-4-yl]benzonitrile
"A110"	2-Cyclobutylmethoxy-5-{2-[1-(2-methoxyethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}benzonitrile
"A111"	2-Cyclobutylmethoxy-5-[2-(5-hydroxymethylpyridin-2-ylamino)pyridin-4-yl]benzonitrile
"A112"	2-Cyclobutylmethoxy-5-[2-(1-piperidin-4-yl-1H-pyrazol-4-ylamino)pyridin-4-yl]benzonitrile
"A113"	2-Cyclobutylmethoxy-5-[2-(5-morpholin-4-ylpyridin-2-ylamino)pyridin-4-yl]benzonitrile
"A114"	2-(1-Acetylpiperidin-4-ylmethoxy)-5-{2-[1-(2-methoxyethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}benzonitrile
"A115"	2-(1-Acetylpiperidin-4-ylmethoxy)-5-[2-(5-hydroxymethylpyridin-2-ylamino)pyridin-4-yl]benzonitrile
"A116"	2-(1-Acetylpiperidin-4-ylmethoxy)-5-[2-(1-piperidin-4-yl-1H-pyrazol-4-ylamino)pyridin-4-yl]benzonitrile
"A117"	2-(1-Acetylpiperidin-4-ylmethoxy)-5-[2-(5-morpholin-4-ylpyridin-2-ylamino)pyridin-4-yl]benzonitrile
"A118"	5-[2-(5-Morpholin-4-ylmethylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.


10. Process for the preparation of compounds of the formula I according to Claims 1-9 and pharmaceutically usable salts, tautomers and stereoisomers thereof, characterised in that

a) a compound of the formula II



in which Y and R² have the meanings indicated in Claim 1,

is reacted with a compound of the formula III



III

in which R¹ has the meaning indicated in Claim 1 and

L denotes F, Cl, Br or I,

and/or

a base or acid of the formula I is converted into one of its salts.

11. Medicaments comprising at least one compound of the formula I according to Claim 1-9 and/or pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

12. Compounds according to Claim 1-9 and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use for the treatment of cancer, septic shock, primary open angle glaucoma (POAG), hyperplasia, atherosclerosis, retinopathy, osteoarthritis, endometriosis, chronic inflammation, neurodegenerative diseases, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren's syndrome, Aicardi-Goutières syndrome, chilblain lupus, retinal vasculopathy, cerebral leukodystrophy (RVCL), systemic sclerosis, myositis, psoriasis, chronic obstructive pulmonary disease (CPD), inflammatory bowel disease (IBD), obesity, insulin resistance, type 2 diabetes (NIDDM) and/or metabolic syndrome.

13. Compounds of the formula I according to Claim 1-9 and/or physiologically acceptable salts, tautomers and stereoisomers thereof for use for the treatment of tumours, where a therapeutically effective amount of a compound of the formula I is administered in combination with a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibitors.

14. Compounds of the formula I according to Claim 1-9 and/or physiologically acceptable salts, tautomers and stereoisomers thereof for use for the treatment of tumours, where a therapeutically effective amount of a compound of the formula 1 is administered in combination with radiotherapy and a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibitors.




PATENT CLAIMS





1. Compounds selected from the group

Compound No.	Name and/or structure
"A1"	2-(Tetrahydropyran-4-yloxy)-5-{2-[1-(3-trifluoromethylphenyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}benzonitrile
"A2"	5-{2-[1-(1-Methylpiperidin-4-yl)-1H-pyrazol-4-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A3"	5-[2-([3,3']Bipyridinyl-6-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A4"	5-[2-(5-Methylisoxazol-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A5"	5-[2-(1-Methyl-1H-pyrazol-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A6"	5-[2-(2-Furan-2-ylmethyl-2H-pyrazol-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A7"	5-[2-(5-Morpholin-4-ylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A8"	5-[2-(1-Phenyl-1H-pyrazol-4-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A9"	5-{2-[5-(1H-Pyrazol-4-yl)pyridin-2-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A10"	5-[2-(5-tert-Butyl-1H-pyrazol-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A11"	6-{4-[3-Cyano-4-(tetrahydropyran-4-yloxy)phenyl]pyridin-2-ylamino}nicotinonitrile
"A12"	5-[2-(5-Cyclopropyl-2H-pyrazol-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A13"	2-(Tetrahydropyran-4-yloxy)-5-[2-(5-trifluoromethylpyridin-2-ylamino)pyridin-4-yl]benzonitrile
"A14"	5-[2-(Pyrimidin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A15"	5-[2-(5-Hydroxymethylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A16"	5-[2-(1-Piperidin-4-yl-1H-pyrazol-4-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile

"A17"	2-{4-[3-Cyano-4-(tetrahydropyran-4-yloxy)phenyl]pyridin-2-yl-amino}isonicotinonitrile
"A18"	5-[2-(4-Hydroxymethylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A19"	5-{4-[3-Cyano-4-(tetrahydropyran-4-yloxy)phenyl]pyridin-2-yl-amino}benzofuran-2-carboxamide
"A20"	5-{2-[1-(2,2-Difluoroethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A21"	5-{2-[1-(2-Piperidin-4-ylethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A22"	5-{2-[1-(2-Morpholin-4-ylethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A23"	5-{2-[1-(3-Methoxypropyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A24"	5-{2-[1-(2-Cyanocyclopropylmethyl)-1H-pyrazol-4-ylamino]-pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A25"	5-[2-(1-Azetidin-3-yl-1H-pyrazol-4-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A26"	5-{2-[1-((1S,2S)-2-Hydroxymethylcyclopropylmethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)-benzonitrile
"A27"	5-{2-[1-(Tetrahydrofuran-3-ylmethyl)-1H-pyrazol-4-ylamino]-pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A28"	5-[2-(1-Pyrrolidin-3-yl-1H-pyrazol-4-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A29"	5-[2-(1-{2-[1-(2-Hydroxyacetyl)piperidin-4-yl]ethyl}-1H-pyrazol-4-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A30"	5-[2-(1-{2-[1-(2-Aminoacetyl)piperidin-4-yl]ethyl}-1H-pyrazol-4-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A31"	5-[2-(3-tert-Butylisoxazol-5-ylamino)pyridin-4-yl]-2-(tetrahydro-pyran-4-yloxy)benzonitrile

"A32"	2-(Tetrahydropyran-4-yloxy)-5-{2-[1-(3-trifluoromethylphenyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}benzonitrile
"A33"	5-[2-(1-Methyl-1H-pyrazol-3-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A34"	5-[2-(1H-Pyrazol-4-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A35"	5-{2-[1-(2-Methoxyethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A36"	2-(Tetrahydropyran-4-yloxy)-5-[2-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-ylamino)pyridin-4-yl]benzonitrile
"A37"	6-{4-[3-Cyano-4-(tetrahydropyran-4-yloxy)phenyl]pyridin-2-ylamino}nicotinamide
"A38"	5-[2-[1-(2-Pyrazol-1-ylethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A39"	5-[2-[1-(2-Morpholin-4-ylethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A40"	5-[2-(1-Pyrrolidin-3-yl-1H-pyrazol-4-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A41"	5-{2-[1-(Tetrahydrofuran-3-ylmethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A42"	5-{4-[3-Cyano-4-(tetrahydropyran-4-yloxy)phenyl]pyrimidin-2-ylamino}benzofuran-2-carboxamide
"A43"	5-[2-[1-(2-Pyrazol-1-ylethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A44"	5-[2-[1-(2,2-Difluoroethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A45"	5-[2-[1-(2-Piperidin-4-ylethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A46"	5-[2-[1-(3-Methoxypropyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile

"A47"	5-{2-[5-(3,6-Dihydro-2H-pyran-4-yl)pyridin-2-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A48"	5-[2-(1',2',3',6'-Tetrahydro-[3,4']bipyridinyl-6-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A53"	
"A58"	
"A59"	

"A60"	 <p>Chemical structure of compound A60: A 4-cyano-2-(4-(3-methoxypropyl)-1H-imidazol-2-yl)pyridine. It features a pyridine ring substituted at the 2-position with an imidazole ring, which is further substituted at the 3-position with a 3-methoxypropyl group. The pyridine ring is also substituted at the 4-position with a cyano group.</p>
"A61"	 <p>Chemical structure of compound A61: A 4-cyano-2-(4-(hydroxymethyl)pyridin-2-yl)pyridine. It features a pyridine ring substituted at the 2-position with an imidazole ring, which is further substituted at the 3-position with a hydroxymethyl group. The pyridine ring is also substituted at the 4-position with a cyano group.</p>
"A62"	 <p>Chemical structure of compound A62: A 4-cyano-2-(4-(4-(hydroxymethyl)pyridin-2-yl)-1H-imidazol-2-yl)pyridine. It features a pyridine ring substituted at the 2-position with an imidazole ring, which is further substituted at the 3-position with a 4-(hydroxymethyl)pyridin-2-yl group. The pyridine ring is also substituted at the 4-position with a cyano group.</p>
"A63"	 <p>Chemical structure of compound A63: A 4-cyano-2-(4-(4-(morpholin-4-yl)pyridin-2-yl)pyridin-2-yl)pyridine. It features a pyridine ring substituted at the 2-position with an imidazole ring, which is further substituted at the 3-position with a 4-(4-(morpholin-4-yl)pyridin-2-yl) group. The pyridine ring is also substituted at the 4-position with a cyano group.</p>

"A64"	5-[2-(1-Piperidin-4-yl-1H-pyrazol-4-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A65"	2-[4-[3-Cyano-4-(tetrahydropyran-4-yloxy)phenyl]pyridin-2-yl-amino]isonicotinic acid
"A66"	5-[2-(5-Piperidin-4-ylpyrimidin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A67"	5-[2-[1-[(1S,2S)-2-Hydroxymethylcyclopropylmethyl]-1H-pyrazol-4-ylamino]pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)-benzonitrile
"A68"	5-[2-(1-Methyl-6-oxo-1,6-dihydropyridazin-3-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A69"	5-[2-(6-Oxo-1,6-dihydropyridazin-3-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A70"	5-[2-(4-Hydroxymethylpyridin-2-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A71"	5-[2-(6-Piperidin-4-ylpyridazin-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A72"	5-[2-(5-Piperidin-4-ylpyrazin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A73"	5-[2-[1-(4-Hydroxycyclohexyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A74"	5-[2-(1',2',3',4',5',6'-Hexahydro-[4,4']bipyridinyl-2-ylamino)-pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A75"	5-[2-[1-(2-Hydroxyethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A76"	5-[2-(2-Methoxy-1',2',3',6'-tetrahydro-[3,4']bipyridinyl-6-ylamino)-pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A77"	5-[2-(4-Aminomethylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A78"	5-[2-(1'-Methyl-1',2',3',4',5',6'-hexahydro-[4,4']bipyridinyl-2-yl-amino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile

"A79"	5-{2-[1-(2-Hydroxyethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A80"	5-[2-(5-Methylisoxazol-3-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A81"	5-[2-(4-Dimethylaminomethylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A82"	5-[2-(4-Morpholin-4-ylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A83"	5-{2-[1-(2-Pyrrolidin-1-ylethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A84"	5-[2-[4-(4-Methylpiperazin-1-yl)pyridin-2-ylamino]pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A85"	5-[2-(6-Morpholin-4-ylpyrazin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A86"	5-[2-[4-(5,6-Dihydro-4H-pyran-2-yl)pyridin-2-ylamino]pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A87"	5-[2-(4-Cyclopropylthiazol-2-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A88"	5-[2-[5-(2-Oxa-6-azaspiro[3.3]hept-6-ylmethyl)pyridin-2-ylamino]pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A89"	5-[2-(4-Piperidin-4-ylpyrimidin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A90"	5-[2-(6-Morpholin-4-ylpyridazin-3-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A91"	5-[2-(1',2',3',4',5',6'-Hexahydro-[2,4']bipyridinyl-6-ylamino)-pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A92"	5-[2-[6-(5,6-Dihydro-4H-pyran-2-yl)pyrazin-2-ylamino]pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A93"	5-[2-(4-Methyloxazol-2-ylamino)pyrimidin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile


"A94"	2-Cyclobutylmethoxy-5-{2-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl-amino]pyrimidin-4-yl}benzonitrile
"A95"	2-Cyclobutylmethoxy-5-{2-[1-((1S,2S)-2-hydroxymethylcyclopropylmethyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}benzonitrile
"A96"	5-[2-(6-Piperidin-4-ylpyrazin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A97"	2-Cyclobutylmethoxy-5-{2-[1-(4-hydroxycyclohexyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}benzonitrile
"A98"	2-(Tetrahydropyran-4-yloxy)-5-{2-[5-(tetrahydropyran-4-yl)-pyrazin-2-ylamino]pyridin-4-yl}benzonitrile
"A99"	5-[2-(5-Hydroxymethylpyrazin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A100"	2-(Tetrahydropyran-4-yloxy)-5-{2-[6-(tetrahydropyran-4-yl)-pyridazin-3-ylamino]pyridin-4-yl}benzonitrile
"A101"	5-{2-[1-(4-Hydroxycyclohexyl)-1H-pyrazol-4-ylamino]pyrimidin-4-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile
"A102"	5-[2-(3-Hydroxymethylpyrazin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile
"A103"	2-Cyclobutylmethoxy-5-{2-[1-(2-methoxyethyl)-1H-pyrazol-4-yl-amino]pyrimidin-4-yl}benzonitrile
"A104"	2-Cyclopropylmethoxy-5-[2-(1H-pyrazol-4-ylamino)pyridin-4-yl]-benzonitrile
"A105"	2-Cyclopropylmethoxy-5-{2-[1-(2-methoxyethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl}benzonitrile
"A106"	2-Cyclopropylmethoxy-5-[2-(5-hydroxymethylpyridin-2-ylamino)-pyridin-4-yl]benzonitrile
"A107"	2-Cyclopropylmethoxy-5-[2-(1-piperidin-4-yl-1H-pyrazol-3-yl-amino)pyridin-4-yl]benzonitrile
"A108"	2-Cyclopropylmethoxy-5-[2-(5-morpholin-4-ylpyridin-2-ylamino)-pyridin-4-yl]benzonitrile

"A109"	2-Cyclobutylmethoxy-5-[2-(1H-pyrazol-4-ylamino)pyridin-4-yl]-benzonitrile
"A110"	2-Cyclobutylmethoxy-5-[2-[1-(2-methoxyethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl]benzonitrile
"A111"	2-Cyclobutylmethoxy-5-[2-(5-hydroxymethylpyridin-2-ylamino)-pyridin-4-yl]benzonitrile
"A112"	2-Cyclobutylmethoxy-5-[2-(1-piperidin-4-yl-1H-pyrazol-4-yl-amino)pyridin-4-yl]benzonitrile
"A113"	2-Cyclobutylmethoxy-5-[2-(5-morpholin-4-ylpyridin-2-ylamino)-pyridin-4-yl]benzonitrile
"A114"	2-(1-Acetylpiperidin-4-ylmethoxy)-5-[2-[1-(2-methoxyethyl)-1H-pyrazol-4-ylamino]pyridin-4-yl]benzonitrile
"A115"	2-(1-Acetylpiperidin-4-ylmethoxy)-5-[2-(5-hydroxymethylpyridin-2-ylamino)pyridin-4-yl]benzonitrile
"A116"	2-(1-Acetylpiperidin-4-ylmethoxy)-5-[2-(1-piperidin-4-yl-1H-pyrazol-4-ylamino)pyridin-4-yl]benzonitrile
"A117"	2-(1-Acetylpiperidin-4-ylmethoxy)-5-[2-(5-morpholin-4-ylpyridin-2-ylamino)pyridin-4-yl]benzonitrile
"A118"	5-[2-(5-Morpholin-4-ylmethylpyridin-2-ylamino)pyridin-4-yl]-2-(tetrahydropyran-4-yloxy)benzonitrile

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. Process for the preparation of compounds and pharmaceutically usable salts, tautomers and stereoisomers thereof according to Claim 1, characterised in that


a) a compound of the formula II



in which Y denotes Het²-diyl,

and R² denotes H, A, Ar¹, (CH₂)_nHet³, CN, (CH₂)_nCyc, CONH₂, COOA, (CH₂)_nOH, (CH₂)_nOA, (CH₂)_nNH₂, (CH₂)_nNHA or (CH₂)_nNA₂

is reacted with a compound of the formula III



R¹ denotes O(CH₂)_nHet¹, NH(CH₂)_nHet¹, OA, NHA, NA₂, O(CH₂)_nCyc or NH(CH₂)_nCyc

L denotes F, Cl, Br or I,

and/or

a base or acid of the formula I is converted into one of its salts.

3. Medicaments comprising at least one compound of the compounds and/or pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, according to Claim 1, and optionally excipients and/or adjuvants.

4. Compounds and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, according to Claim 1, for

use for the treatment of cancer, septic shock, primary open angle glaucoma (POAG), hyperplasia, atherosclerosis, retinopathy, osteoarthritis, endometriosis, chronic inflammation, neurodegenerative diseases, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren's syndrome, Aicardi-Goutières syndrome, chilblain lupus, retinal vasculopathy, cerebral leukodystrophy (RVCL), systemic sclerosis, myositis, psoriasis, chronic obstructive pulmonary disease (CPD), inflammatory bowel disease (IBD), obesity, insulin resistance, type 2 diabetes (NIDDM) and/or metabolic syndrome.

5. Compounds and/or physiologically acceptable salts, tautomers and stereoisomers thereof according to Claim 1 for use for the treatment

of tumours, where a therapeutically effective amount of a compound of the formula I is administered in combination with a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibitors.

6. Compounds and/or physiologically acceptable salts, tautomers and stereoisomers thereof, according to Claim 1, for use for the treatment

of tumours, where a therapeutically effective amount of a compound of the formula 1 is administered in combination with radiotherapy and a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibitors.